202 related articles for article (PubMed ID: 10964871)
1. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.
Henry ME; Moore CM; Kaufman MJ; Michelson D; Schmidt ME; Stoddard E; Vuckevic AJ; Berreira PJ; Cohen BM; Renshaw PF
Am J Psychiatry; 2000 Sep; 157(9):1506-8. PubMed ID: 10964871
[TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Judge R; Parry MG; Quail D; Jacobson JG
Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period.
Kreider MS; Bushnell WD; Oakes R; Wheadon DE
J Clin Psychiatry; 1995 Apr; 56(4):142-5. PubMed ID: 7713852
[TBL] [Abstract][Full Text] [Related]
6. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn S
Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
[TBL] [Abstract][Full Text] [Related]
8. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
Fava M; Amsterdam JD; Deltito JA; Salzman C; Schwaller M; Dunner DL
Ann Clin Psychiatry; 1998 Dec; 10(4):145-50. PubMed ID: 9988054
[TBL] [Abstract][Full Text] [Related]
9. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Strauss WL; Unis AS; Cowan C; Dawson G; Dager SR
Am J Psychiatry; 2002 May; 159(5):755-60. PubMed ID: 11986128
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.
Gülseren L; Gülseren S; Hekimsoy Z; Mete L
Arch Med Res; 2005; 36(2):159-65. PubMed ID: 15847950
[TBL] [Abstract][Full Text] [Related]
11. Serotonin reuptake inhibitor-related extrapyramidal side effects in two patients with cerebral palsy.
Rone LA; Ferrando SJ
Psychosomatics; 1996; 37(2):165-6. PubMed ID: 8742546
[No Abstract] [Full Text] [Related]
12. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
De Wilde J; Spiers R; Mertens C; Bartholomé F; Schotte G; Leyman S
Acta Psychiatr Scand; 1993 Feb; 87(2):141-5. PubMed ID: 8447241
[TBL] [Abstract][Full Text] [Related]
13. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.
Henry ME; Kaufman MJ; Hennen J; Michelson D; Schmidt ME; Stoddard E; Vukovic AJ; Barreira PJ; Cohen BM; Renshaw PF
Biol Psychiatry; 2003 Jan; 53(1):100-5. PubMed ID: 12513950
[TBL] [Abstract][Full Text] [Related]
14. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
15. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
Kaufman MJ; Henry ME; Frederick Bd; Hennen J; Villafuerte RA; Stoddard EP; Schmidt ME; Cohen BM; Renshaw PF
Biol Psychiatry; 2003 Sep; 54(5):534-9. PubMed ID: 12946882
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
19. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
Bordet R; Thomas P; Dupuis B
Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Bogetto F; Bellino S; Revello RB; Patria L
CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
